---
id: 099
title: Transplant Infections by Timeline
category: clinical_syndromes
subcategory: transplant
tags: [transplant, opportunistic-infections, CMV, aspergillus, timeline, prophylaxis]
difficulty: medium
---

## Question

What infections occur by transplant timeline? Use the **"<1 Month = Nosocomial, 1-6 Months = Opportunistic, >6 Months = Community"** framework.

## Answer

### **Transplant Infection Timeline:**

**<1 Month (Early Post-Transplant):**
- **Nosocomial/surgical complications**
- **Donor-derived** infections
- **Pre-existing infections** (reactivation)

**Common Pathogens:**
- Surgical site infections (*S. aureus*, Gram-negatives)
- CLABSI, CAUTI, VAP (nosocomial pathogens)
- *Candida* (especially if recipient on broad-spectrum antibiotics)
- ***Aspergillus*** (especially lung transplant)

**1-6 Months (Peak Immunosuppression):**
- **Opportunistic infections** (most common period)
- **Viral reactivation** (CMV, EBV, BK virus)

**Common Pathogens:**

| Pathogen | Presentation | Prophylaxis |
|----------|--------------|-------------|
| **CMV** | Fever, leukopenia, organ involvement (colitis, pneumonitis, hepatitis) | **Valganciclovir 900mg daily** × 3-6 months (high-risk D+/R-) |
| ***Pneumocystis jirovecii*** | Dyspnea, bilateral infiltrates | **TMP-SMX DS daily** (or 3×/week) × 6-12 months |
| ***Aspergillus*** | Pulmonary nodules, cavitation | **Voriconazole** (lung transplant, high-risk) |
| **BK virus** | Hemorrhagic cystitis (HSCT), nephropathy (kidney transplant) | No prophylaxis, reduce immunosuppression |
| **EBV** | PTLD (post-transplant lymphoproliferative disorder) | Monitor EBV viral load |
| ***Toxoplasma*** | Encephalitis (if D+/R-) | **TMP-SMX** (also prevents PCP) |

**>6 Months (Late Post-Transplant):**
- **Community-acquired infections** (similar to general population)
- **Chronic viral infections** (CMV, EBV, hepatitis)
- **Late opportunistic infections** (if ongoing immunosuppression)

**Common:**
- Community-acquired pneumonia (*S. pneumoniae*, *H. influenzae*)
- Influenza, COVID-19
- Urinary tract infections
- Cryptococcus, endemic fungi (if high-risk geography)

## Key Points

### **CMV Risk Stratification:**
- **High-risk (D+/R-):** Donor CMV+, Recipient CMV- → **Valganciclovir prophylaxis × 3-6 months**
- **Intermediate-risk (R+):** Recipient CMV+ → **Preemptive therapy** (monitor CMV PCR weekly, treat if detected)
- **Low-risk (D-/R-):** Both negative → No prophylaxis

### **Universal Prophylaxis Post-Transplant:**
- ***Pneumocystis*:** **TMP-SMX DS daily** (or 3×/week) × 6-12 months (lifelong if ongoing immunosuppression)
- **CMV (high-risk):** **Valganciclovir** × 3-6 months
- ***Candida*:** **Fluconazole** × 3-6 months (abdominal transplant, high-risk)

### **Clinical Pearls:**
- **<1 month:** Nosocomial (surgical, donor-derived)
- **1-6 months:** Opportunistic (CMV, PCP, *Aspergillus*)
- **>6 months:** Community-acquired (but OIs if immunosuppression continues)
- **CMV D+/R-:** Highest risk → valganciclovir prophylaxis
- **TMP-SMX** prevents both PCP + *Toxoplasma*
- **Monitor CMV viral load** weekly in high-risk patients

## Sources

- [AST: Infectious Diseases Guidelines for Transplantation 2024]
- [IDSA: Transplant Infectious Diseases 2023]

## Media

N/A
